Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 ADC”

117 trials

Showing 20 of 117 results

Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Early research (Phase 1)Study completedNCT03383692
What this trial is testing

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Who this might be right for
Neoplasm Metastasis
Daiichi Sankyo Co., Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Testing effectiveness (Phase 2)UnknownNCT06178601
What this trial is testing

RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Shanxi Province Cancer Hospital 36
Not applicableLooking for participantsNCT07379268
What this trial is testing

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Who this might be right for
Bladder Cancer
Qilu Hospital of Shandong University 224
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05356351
What this trial is testing

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Who this might be right for
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07019337
What this trial is testing

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 100
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Not applicableNot Yet RecruitingNCT06492447
What this trial is testing

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

Who this might be right for
HER 2 Low-expressing Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)UnknownNCT05263869
What this trial is testing

MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Who this might be right for
Breast Cancer With Liver Metastases
Shanghai Miracogen Inc. 99
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)Looking for participantsNCT07471776
What this trial is testing

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)
Fudan University 45
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Testing effectiveness (Phase 2)Study completedNCT03556345
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 127
Early research (Phase 1)Ended earlyNCT03284723
What this trial is testing

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Who this might be right for
Breast Neoplasms
Pfizer 95
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation